Compare BIO & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIO | EVR |
|---|---|---|
| Founded | 1952 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 11.7B |
| IPO Year | N/A | 2006 |
| Metric | BIO | EVR |
|---|---|---|
| Price | $299.95 | $342.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $358.50 | $332.22 |
| AVG Volume (30 Days) | 170.4K | ★ 349.0K |
| Earning Date | 10-29-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | N/A | ★ 61.11 |
| EPS | N/A | ★ 12.55 |
| Revenue | $2,557,500,000.00 | ★ $3,542,875,000.00 |
| Revenue This Year | $1.77 | $25.39 |
| Revenue Next Year | $2.30 | $16.43 |
| P/E Ratio | ★ N/A | $27.28 |
| Revenue Growth | N/A | ★ 27.03 |
| 52 Week Low | $211.43 | $148.63 |
| 52 Week High | $373.69 | $364.42 |
| Indicator | BIO | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 63.45 |
| Support Level | $298.02 | $330.45 |
| Resistance Level | $307.78 | $343.09 |
| Average True Range (ATR) | 8.35 | 10.61 |
| MACD | -2.13 | 0.72 |
| Stochastic Oscillator | 16.30 | 77.71 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.